Cardiovascular

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients with atrial fibrillation (AFib).

Patient outcomes appeared to be more heavily driven by breast cancer stage than delays in diagnosis, researchers found.

The health equity impact of the polypill is significant; by effectively controlling cardiovascular disease (CVD) risk factors in populations with limited health care access, there's potential to reduce income- and race-related health disparities.

Americans who drank coffee in the morning had a lower overall mortality compared with those who drank coffee later in the day.

This year's top 5 most-read cardiovascular articles explored topics ranging from FDA approvals to the risks associated with the sugar alcohol xylitol and beyond.

Our top content from the 100th annual American Heart Association (AHA) Scientific Sessions included exclusive expert insights and highlighted promising treatments.

Dan Bloomfield, MD, chief medical officer, Anthos, walks through promising findings demonstrating the efficacy of abelacimab, a factor XI (FXI) inhibitor, to reduce bleeding risk in atrial fibrillation treatment.

Study identifies underutilization of testing, with disparities by race and sex.

Using direct oral anticoagulants as a case study, the authors examined how delayed adoption of novel treatments could impact patient health outcomes and cost.

The top 5 most-viewed content from this year's American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease (CVD) Prevention included interviews with Robert Kushner, MD, MS, and Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC, as well as coverage on multiple areas of cardiovascular medicine.

Data presented at the 2024 American Heart Association (AHA) Scientific Sessions showed that continuous treatment with acoramidis (Attruby; BridgeBio Pharma) significantly reduced the risk of all-cause mortality (ACM) and cardiovascular-related hospitalizations (CVH) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).

Metformin and lifestyle changes show no significant impact on atrial fibrillation (AFib) burden or progression compared with standard care.

With approval, acoramaidis (Attruby; BridgeBio Pharma) becomes the first agent with a label specifying near-complete stabilization of transthyretin (TTR).

Adults with more unfavorable health-related social needs, such as unemployment or food insecurity, had a higher prevalence of low cardiovascular health, highlighting the importance of addressing social determinants to improve population health.

Evidence highlights the predictive value of the stress hyperglycemia ratio for mortality risk in patients with acute myocardial infarction, ischemic stroke, and acute heart failure.

New study findings reveal that the risk of cardiovascular disease among light ex-smokers aligns quickly with never-smokers, while heavy ex-smokers may take over 25 years to reach the same level.

A new study has linked work-related stress to poorer cardiovascular health, highlighting the need for workplace wellness programs to reduce the risk of cardiovascular disease.

A new study assesses the prognostic accuracy of Predicting Risk of CVD EVENTs (PREVENT) equations for predicting cardiovascular disease (CVD) mortality in the US population.

Viet Le, PA-C, Intermountain Health, gives insights into the benefits cardio-renal-metabolic care models provide for patients in need.

Two posters presented at the CHEST 2024 annual meeting highlighted significant disparities in acute coronary syndrome care and outcomes among different racial, ethnic, and gender groups, underscoring the urgent need for targeted interventions to address these inequities.

This article describes the positive impact that actively managing functional recovery has on postacute placement for patients undergoing coronary artery bypass surgery.

Hemolysis, elevated liver enzymes, low platelet (HELLP) syndrome, and severe preeclampsia significantly elevate cardiovascular risk during delivery, study finds.

Despite reductions in deaths from cancer and cardiovascular diseases, increased mortality from assaults, accidents, and the COVID-19 pandemic has widened disparities in health outcomes for Black individuals.

Higher levels of lipoprotein(a) (Lp[a]) were found to be associated with a continuously increasing risk of recurrent atherosclerotic cardiovascular disease (ASCVD) events.

A collection of research by Helen Hobbs, MD, highlights how genetic mutations influence cholesterol levels and impact heart disease risk, offering insights into lifelong cardiovascular health management.